---
title: "Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295926197.md"
description: "Recently published data on the next-generation STAT3 inhibitor, TTI-109, revealed promising results in healthy volunteers. The study demonstrated the efficacy of the prodrug design, showing improved tolerability in participants. Additionally, significant reductions in disease-relevant immune cell populations were observed. These findings highlight the potential of TTI-109 as a treatment for various conditions. This represents a significant advancement in the field of drug development, with potential implications for a wide range of diseases."
datetime: "2026-08-14T11:01:39.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295926197.md)
  - [en](https://longbridge.com/en/news/295926197.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295926197.md)
generator: "portal-rs"
---

# Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update

Recently published data on the next-generation STAT3 inhibitor, TTI-109, revealed promising results in healthy volunteers. The study demonstrated the efficacy of the prodrug design, showing improved tolerability in participants. Additionally, significant reductions in disease-relevant immune cell populations were observed. These findings highlight the potential of TTI-109 as a treatment for various conditions. This represents a significant advancement in the field of drug development, with potential implications for a wide range of diseases.

### Related Stocks

- [TVRD.US](https://longbridge.com/en/quote/TVRD.US.md)

## Related News & Research

- [Tvardi Therapeutics to attend Wells Fargo, Cantor global healthcare investor conferences](https://longbridge.com/en/news/297041866.md)
- [Biovica signs master services agreement with US biotech subsidiary for cancer drug development testing services](https://longbridge.com/en/news/297162314.md)
- [Endovia Health opens FDA INAD file for CannEpil veterinary program](https://longbridge.com/en/news/296915045.md)
- [More US employers to drop weight-loss drugs in 2027, as healthcare costs increase](https://longbridge.com/en/news/297195024.md)
- [Oost NL provides follow-on financing for GlycoTherapeutics to advance cancer drug candidate](https://longbridge.com/en/news/297175970.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**